Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $1.86 and last traded at $1.88, with a volume of 258277 shares changing hands. The stock had previously closed at $1.95.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AUTL shares. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Down 4.8 %

The stock has a fifty day moving average of $2.20 and a 200-day moving average of $3.16. The stock has a market capitalization of $476.30 million, a PE ratio of -1.48 and a beta of 2.02.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. TFG Asset Management GP Ltd raised its position in Autolus Therapeutics by 3.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock valued at $19,388,000 after purchasing an additional 250,000 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Autolus Therapeutics by 4.8% in the fourth quarter. Two Sigma Advisers LP now owns 333,400 shares of the company’s stock valued at $783,000 after buying an additional 15,400 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Autolus Therapeutics by 23.8% in the fourth quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock valued at $2,131,000 after buying an additional 174,485 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $581,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $85,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.